Abstract | OBJECTIVES: METHODS: The impact of baseline (age, prior AUR, prostate-specific antigen tertiles, lower urinary tract symptoms severity, and bother score) and dynamic (International Prostate Symptom Score [IPSS] worsening of 4 points or greater and bother greater than 3 during treatment) variables on the risk of AUR/BPH-related surgery was assessed using Kaplan-Meier curves and log-rank tests. Associated hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard models. RESULTS: Of the 3514 men analyzed, 140 (4%) experienced a first episode of conservatively managed AUR before inclusion. Of those 140 men, 5 (3.6%) had AUR relapse during alfuzosin treatment and 6 (4.3%) underwent BPH-related surgery. Of those 3374 men without prior AUR, 19 (0.6%) experienced AUR during treatment and 41 (1.2%) underwent BPH-related surgery. During treatment, the most important predictors of AUR were prior AUR (HR 6.35, 95% CI 2.31 to 17.40; P < 0.01), IPSS worsening of 4 or greater (HR 3.34, 95% CI 1.11 to 9.99; P = 0.03), and bother score greater than 3 (HR 3.32, 95% CI 1.29 to 8.53; P < 0.01) at endpoint. Other variables (age, PSA, baseline IPSS, and bother) had much less predictive value. Similar results were observed regarding the risk of AUR and/or BPH-related surgery. CONCLUSIONS: The results of this 6-month real life practice study suggest that prior AUR and symptom deterioration during treatment with alfuzosin 10 mg once-daily (IPSS worsening of 4 or more points, bother score greater than 3) were the strongest predictors of AUR and AUR/BPH-related surgery in men with lower urinary tract symptoms.
|
Authors | Mark Emberton, Mostafa Elhilali, Haim Matzkin, Niels Harving, Jeroen van Moorselaar, Rudolf Hartung, Antonio Alcaraz, Guy Vallancien, Alf-One Study Group |
Journal | Urology
(Urology)
Vol. 66
Issue 2
Pg. 316-22
(Aug 2005)
ISSN: 1527-9995 [Electronic] United States |
PMID | 16098361
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Quinazolines
- alfuzosin
|
Topics |
- Acute Disease
- Adrenergic alpha-Antagonists
(administration & dosage)
- Adult
- Aged
- Aged, 80 and over
- Drug Administration Schedule
- Humans
- Male
- Middle Aged
- Prostatic Hyperplasia
(complications, drug therapy, surgery)
- Quinazolines
(administration & dosage)
- Urinary Retention
(etiology, surgery)
- Urination Disorders
(drug therapy, etiology)
|